FIELD: biochemistry.
SUBSTANCE: invention relates to humanized and/or deimmunized antibodies, antibody fragments or antibody derivatives that bind to a prostate specific membrane antigen (PSMA), and to processes for using these antibodies, antibody fragments or antibody derivatives in the treatment of prostate cancer and other neoplastic tumours, as well as neurological diseases.
EFFECT: invention provides humanized antibodies, antibody fragments or antibody derivatives that bind to a prostate specific membrane antigen (PSMA) with high affinity, in particular an epitope of the PSMA extracellular domain.
24 cl, 7 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| METHOD OF PURIFICATION FOR REMOVING TYROSINE SULPHATED ANTIBODIES VARIANTS, PURIFIED COMPOSITIONS | 2017 |
|
RU2793400C2 |
| COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS | 2015 |
|
RU2764981C1 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| ISOLATED HUMAN CD45RC ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF, IN VITRO METHOD OF DETECTING hCD45RC | 2019 |
|
RU2826421C2 |
